Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine versus CMF for advanced breast cancer in women unsuitable for intensive chemotherapy
ACTRN12606000379516Phase 3Completed
- Sponsor
- Breast Cancer Trials
- Start
- Jun 2001
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of capecitabine, cyclophosphamide, methotrexate, fluorouracil and prednisone in breast cancer (3 arms), sponsored by Breast Cancer Trials. Primary endpoint: Quality-adjusted time to progression. Started Jun 2001; status: completed.
02
Drugs
capecitabinecyclophosphamidemethotrexatefluorouracilprednisone
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000379516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000379516.